Literature DB >> 15046429

Metal-on-metal resurfacing of the hip in patients under the age of 55 years with osteoarthritis.

J Daniel1, P B Pynsent, D J W McMinn.   

Abstract

The results of conventional hip replacement in young patients with osteoarthritis have not been encouraging even with improvements in the techniques of fixation and in the bearing surfaces. Modern metal-on-metal hip resurfacing was introduced as a less invasive method of joint reconstruction for this particular group. This is a series of 446 hip resurfacings (384 patients) performed by one of the authors (DJWM) using cemented femoral components and hydroxyapatite-coated uncemented acetabular components with a maximum follow-up of 8.2 years (mean 3.3). Their survival rate, Oxford hip scores and activity levels are reviewed. Six patients died due to unrelated causes. There was one revision (0.02%) out of 440 hips. The mean Oxford score of the surviving 439 hips is 13.5. None of the patients were told to change their activities at work or leisure; 31% of the men with unilateral resurfacings and 28% with bilateral resurfacings were involved in jobs that they considered heavy or moderately heavy; 92% of men with unilateral hip resurfacings and 87% of the whole group participate in leisure-time sporting activity. The extremely low rate of failure in spite of the resumption of high level occupational and leisure activities provides early evidence of the suitability of this procedure for young and active patients with arthritis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15046429     DOI: 10.1302/0301-620x.86b2.14600

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  132 in total

1.  [Hip resurfacing arthroplasty].

Authors:  W-C Witzleb; A Knecht; T Beichler; T Köhler; K-P Günther
Journal:  Orthopade       Date:  2004-11       Impact factor: 1.087

2.  Profunda femoris pseudoaneurysm following Birmingham hip resurfacing: an important differential diagnosis for a periarticular cystic mass.

Authors:  M S Thomas; J N O'Hara; A M Davies; Steven L J James
Journal:  Skeletal Radiol       Date:  2011-12-24       Impact factor: 2.199

3.  Revision rate of Birmingham Hip Resurfacing arthroplasty: comparison of published literature and arthroplasty register data.

Authors:  Reinhard Schuh; Daniel Neumann; Rauend Rauf; Jochen Hofstaetter; Nikolaus Boehler; Gerold Labek
Journal:  Int Orthop       Date:  2012-02-22       Impact factor: 3.075

4.  [Durom™ hip resurfacing. Short- to midterm clinical and radiological outcome].

Authors:  J Goronzy; M Stiehler; S Kirschner; K-P Günther
Journal:  Orthopade       Date:  2010-09       Impact factor: 1.087

5.  Bone mineral density in the femoral neck increases after hip resurfacing: a cohort with five-year follow-up.

Authors:  Charles A Willis-Owen; Henry D Atkinson; Roger D Oakeshott
Journal:  Int Orthop       Date:  2010-08-22       Impact factor: 3.075

6.  Sporting and physical activity following hip resurfacing.

Authors:  Noel E Fisher; Vijay V Killampalli; Rakesh K Kundra; Nikolas A Jagodzinski; Keshav Mathur; Alex D Reading
Journal:  Int Orthop       Date:  2010-05-30       Impact factor: 3.075

Review 7.  Survival of hard-on-hard bearings in total hip arthroplasty: a systematic review.

Authors:  Michael G Zywiel; Siraj A Sayeed; Aaron J Johnson; Thomas P Schmalzried; Michael A Mont
Journal:  Clin Orthop Relat Res       Date:  2011-06       Impact factor: 4.176

8.  Intraoperative radiographs for placing acetabular components in hip resurfacing arthroplasty.

Authors:  Thomas P Gross; Fei Liu; Lee Webb
Journal:  Clin Orthop Relat Res       Date:  2011-06       Impact factor: 4.176

9.  Does a plastic drape reduce incidence of heterotopic ossification after hip resurfacing?

Authors:  John S Shields; Ali Mofidi; William G Ward; Riyaz H Jinnah
Journal:  Clin Orthop Relat Res       Date:  2011-06       Impact factor: 4.176

10.  Indications and results of hip resurfacing.

Authors:  D J W McMinn; J Daniel; H Ziaee; C Pradhan
Journal:  Int Orthop       Date:  2010-11-16       Impact factor: 3.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.